glp 1 drugs and bipolar disorder GLP-1 receptor activation linked to lower depression odds How is GLP1 working for

Retatrutide's triple agonist mechanism represents the next potential frontier

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)

About this article Cite this article Wolff Sagy, Y., Lavie, G., Ramot, N

What GLP-1 Does in Your Body Your intestinal L-cells secrete GLP-1 in response to food, particularly when you eat carbohydrates, fats, and proteins

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts

Key mechanisms of action include: AMPK activation Berberine appears to activate adenosine monophosphate-activated protein kinase (AMPK), an enzyme that regulates cellular energy metabolism